Cdc25 phosphatase inhibitors
US7196084B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 26, 2001 |
| Grant date | Mar 27, 2007 |
| Priority date | — |
| Expiry date | Dec 5, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns novel cdc25 phosphatase inhibitors, and in particular cdc25-C, which correspond to the general formula (I) wherein: A represents a carbocyclic aryl radical optionally substituted 1 to 3 times by one or more radicals independently selected among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR1R2 radical wherein R1 and R2 represent a hydrogen atom or an alkyl radical or R1 and R2 form together with the nitrogen atom a heterocycle of 4 to 7 members comprising 1 to 2 heteroatoms, the members required to complete the heterocycle being selected independently among the CR3R4—, —O—, —S and NR5-radicals, R3 and R4 representing independently each time they are involved a hydrogen atom or an alkyl, hydroxy, alkoxy, amino, alkylamino or dialkylamino radical, and R5 representing independently each time it is involved a hydrogen atom or an alkyl radical, or A represents a phenyl radical substituted by a phenyl radical optionally substituted 1 to 3 times by one or more radicals selected independently among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR1R2 radical wherein R1 and R2 represent a hydrogen atom or an alkyl radical; B represents a —(C…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.